Salarius Pharmaceuticals (NASDAQ:SLRX) Stock Price Up 28.5% – Here’s Why

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) shares traded up 28.5% during trading on Monday . The company traded as high as $0.8976 and last traded at $0.8350. 5,993,436 shares were traded during trading, an increase of 867% from the average session volume of 619,609 shares. The stock had previously closed at $0.65.

Analyst Ratings Changes

Several research firms have recently issued reports on SLRX. Weiss Ratings reissued a “sell (e+)” rating on shares of Salarius Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Salarius Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Salarius Pharmaceuticals Price Performance

The company has a 50 day moving average of $0.78 and a two-hundred day moving average of $3.41. The company has a market capitalization of $4.89 million, a PE ratio of -0.02 and a beta of 0.33.

Salarius Pharmaceuticals (NASDAQ:SLRX) last released its earnings results on Friday, November 14th. The company reported ($1.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($33.60) by $31.79.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that target epigenetic and post‐translational modification pathways in cancer. The company’s lead candidate, seclidemstat (SP‐2577), is designed to inhibit lysine‐specific demethylase 1 (LSD1) and modulate the tumor microenvironment, with a primary focus on treating Ewing sarcoma, a rare and aggressive bone and soft tissue cancer affecting children and young adults.